timothy sykes logo
RXRX Rises As Tempus AI Deal Locks In $42M Thumbnail
G Google News

RXRX Rises As Tempus AI Deal Locks In $42M

TIM SYKES•UPDATED OCT. 5, 2026, 12:33 PM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

Recursion Pharmaceuticals Inc. surged as breakthrough AI-driven drug discovery progress fueled bullish sentiment, and stocks have been trading up by 15.47 percent

Key Takeaways

  • Extended Tempus AI data license now runs through 2029/11, giving RXRX longer visibility on platform revenue.
  • Revised economics swap up to $84M in discretionary fees for $42M in committed payments over three years.
  • Tempus gains a new non‑exclusive global license to Recursion’s proprietary RNA foundation model TxFM.
  • RXRX shares climbed about 2.6% after the Tempus announcement, signaling trader approval of the reset terms.
  • Recent Form 4 filings show insider ownership changes at RXRX, though details on direction and size remain unclear.

Candlestick Chart

Live Update At 12:32:34 EDT: On Monday, October 05, 2026 Recursion Pharmaceuticals Inc. stock [NASDAQ: RXRX] is trending up by 15.47%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Recursion Pharmaceuticals, trading as RXRX, is acting like a classic high‑growth, high‑burn biotech platform name. Revenue over the last year sits around $74.26M, but profitability is deeply negative. Gross margin is only 2.9%, and profit margins run near ‑950%, showing that RXRX is still in heavy build‑out mode rather than scaling profits.

On the balance sheet, RXRX carries roughly $545.7M in cash and short‑term investments against total liabilities of about $297.7M. Debt is light, with total debt‑to‑equity at 0.07 and a strong current ratio of 5.0. That tells traders RXRX has runway to keep funding its AI‑driven drug discovery push, even with free cash flow running around ‑$108M for the recent quarter.

More Breaking News

On the chart, RXRX has quietly trended higher from the low $3.10s in mid‑September 2026 to around $4.76 recently. The multiday tape shows a steady staircase pattern: higher lows from $3.14 to above $4.10, and now a breakout push into the mid‑$4s. Intraday, the 5‑minute candles show accumulation, with pre‑market basing near $4.12 and a sustained grind to the high of $4.83. For active traders, RXRX currently trades like a momentum name trying to build a new range above $4.50.

Why Traders Are Watching RXRX After The Tempus Deal

The latest Tempus AI partnership reset turned RXRX from just another speculative biotech chart into a real catalyst play. Recursion Pharmaceuticals extended its data license agreement with Tempus through 2029/11 and, more importantly for traders, changed how the money flows. Instead of chasing up to $84M in discretionary payments over two years, RXRX now receives $42M in committed license fees spread across three years.

That trade‑off matters. For a company like Recursion Pharmaceuticals, predictable cash can be more powerful than a theoretical higher ceiling. The market agreed — RXRX jumped about 2.6% after the news hit, telling traders that Wall Street prefers visibility on the AI‑driven revenue stream.

The deal also expands the reach of Recursion’s technology. Tempus now has a new non‑exclusive, worldwide license to RXRX’s proprietary RNA foundation model, TxFM. That puts Recursion’s RNA engine in front of more real‑world data and, if it delivers, reinforces the RXRX story as an AI‑first drug discovery platform rather than a single‑asset biotech.

For momentum traders, that narrative shift is critical. RXRX now has multi‑year contracted revenue tied directly to its core AI tools, not just one‑off milestones. That can attract funds that screen for platform adoption and recurring‑style revenue, which can fuel more sustained trading volume. At the same time, several recent Form 4 filings show insider or major holder ownership changes in RXRX. Because the public details don’t spell out whether those moves were buys, sells, or equity grants, disciplined traders treat them as neutral — a reminder to watch, not chase stories.

Combine that with the recent grind from the low $3s to the mid‑$4s, and RXRX becomes a textbook watch‑list name: real news, cleaner revenue quality, and a chart that’s waking up.

Conclusion

RXRX sits at an interesting crossroads for active traders. On the fundamental side, Recursion Pharmaceuticals is nowhere near profitability — margins are brutal, and recent quarterly net loss topped $131M with EBITDA around ‑$112.5M. But the balance sheet is strong, cash is deep, and leverage is low, which buys time for the AI‑discovery thesis to play out. In that context, locking in $42M of Tempus AI license payments through 2029 turns a chunk of RXRX’s story from speculative to contracted.

On the tape, RXRX shows what experienced traders love to see after real news: a controlled grind higher, not a one‑and‑done spike. The stock based under $4, then pushed through prior resistance and is now testing a new band in the high $4s with intraday higher lows. If volume stays elevated, Recursion Pharmaceuticals can remain a favored day‑trading and swing‑trading vehicle around headlines on AI models and partnerships.

At the same time, those vague Form 4 filings around RXRX are a reminder not to guess on insider motives without data. The smarter move is to respect price action and risk. As Tim Sykes always says, “Trade like a sniper, not a machine gunner.” That dovetails with his broader trading philosophy: As millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.”. For RXRX, that means waiting for clear levels, reacting to real catalysts like the Tempus deal, and cutting losses fast if the story or the chart breaks. This analysis is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”